Opinion

Video

Patient Monitoring Strategies in BCG-Unresponsive NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Jason Hafron, MD, considers the future for AI in urology
      Jason Hafron, MD, considers the future for AI in urology
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      How recombinant BCG could ease strain of supply issues
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
      John Taylor, III, MD, on novel options in NMIBC
      John Taylor, III, MD, on novel options in NMIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      What a long-term study of patients undergoing RARC reveals about upstaging
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Related Content
      What urologists can expect in Q2 of 2025
      April 7th 2025

      What urologists can expect in Q2 of 2025

      Hannah Clarke Benjamin P. Saylor
      A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      Subcutaneous nivolumab under review in EU for solid tumors
      March 31st 2025

      Subcutaneous nivolumab under review in EU for solid tumors

      Hannah Clarke
      The European Commission must issue a decision on the application on or by June 2, 2025.
      FDA approves durvalumab/chemo for muscle–invasive bladder cancer
      March 28th 2025

      FDA approves durvalumab/chemo for muscle–invasive bladder cancer

      Hannah Clarke
      The approval is supported by results from the phase 3 NIAGARA trial.
      © 2025 MJH Life Sciences

      All rights reserved.